TRADES
Latest Trades
90
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 29 Aug 2022 Sell REGN REGENERON PHARMACEUTICALS 516 0.0113
ARKG 26 Aug 2022 Sell REGN REGENERON PHARMACEUTICALS 1,730 0.0360
ARKG 25 Aug 2022 Sell REGN REGENERON PHARMACEUTICALS 139 0.0030
ARKG 24 Aug 2022 Sell REGN REGENERON PHARMACEUTICALS 1,200 0.0262
ARKG 23 Aug 2022 Sell REGN REGENERON PHARMACEUTICALS 617 0.0138
ARKG 22 Aug 2022 Sell REGN REGENERON PHARMACEUTICALS 4,968 0.1109
ARKG 14 Mar 2022 Sell REGN REGENERON PHARMACEUTICALS INC 4,785 0.0990
ARKG 4 Feb 2022 Sell REGN REGENERON PHARMACEUTICALS INC 3,261 0.0525
ARKG 1 Feb 2022 Sell REGN REGENERON PHARMACEUTICALS INC 1,400 0.0208
ARKG 28 Jan 2022 Sell REGN REGENERON PHARMACEUTICALS INC 3,206 0.0539
ARKG 14 Dec 2021 Sell REGN REGENERON PHARMACEUTICALS INC 4,092 0.0510
ARKG 13 Dec 2021 Sell REGN REGENERON PHARMACEUTICALS INC 12,000 0.1486
ARKG 10 Dec 2021 Sell REGN REGENERON PHARMACEUTICALS INC 9,477 0.1178
ARKG 30 Nov 2021 Sell REGN REGENERON PHARMACEUTICALS INC 5,600 0.0600
ARKG 29 Nov 2021 Sell REGN REGENERON PHARMACEUTICALS INC 15,900 0.1850
ARKG 22 Nov 2021 Sell REGN REGENERON PHARMACEUTICALS INC 17,100 0.1795
ARKG 15 Nov 2021 Sell REGN REGENERON PHARMACEUTICALS INC 21,494 0.2007
ARKG 12 Nov 2021 Sell REGN REGENERON PHARMACEUTICALS INC 6,917 0.0624
ARKG 11 Nov 2021 Sell REGN REGENERON PHARMACEUTICALS INC 15,885 0.1418
ARKG 10 Nov 2021 Sell REGN REGENERON PHARMACEUTICALS INC 11,602 0.0985
ARKG 9 Nov 2021 Sell REGN REGENERON PHARMACEUTICALS INC 17,447 0.1422
ARKG 5 Nov 2021 Sell REGN REGENERON PHARMACEUTICALS INC 24,086 0.1933
ARKG 3 Nov 2021 Sell REGN REGENERON PHARMACEUTICALS INC 34,692 0.3042
ARKG 15 Oct 2021 Sell REGN REGENERON PHARMACEUTICALS INC 13,078 0.1014
ARKG 11 Oct 2021 Sell REGN REGENERON PHARMACEUTICALS INC 24,941 0.2034
ARKG 6 Oct 2021 Sell REGN REGENERON PHARMACEUTICALS INC 30,723 0.2500
ARKG 5 Oct 2021 Sell REGN REGENERON PHARMACEUTICALS INC 19,128 0.1545
ARKG 15 Sep 2021 Sell REGN REGENERON PHARMACEUTICALS INC 24,054 0.1977
ARKG 18 Aug 2021 Sell REGN REGENERON PHARMACEUTICALS INC 19,393 0.1527
ARKG 17 Aug 2021 Sell REGN REGENERON PHARMACEUTICALS INC 25,962 0.2056
ARKG 12 Aug 2021 Sell REGN REGENERON PHARMACEUTICALS INC 42,669 0.3053
ARKG 11 Aug 2021 Sell REGN REGENERON PHARMACEUTICALS INC 13,326 0.0941
ARKG 10 Aug 2021 Sell REGN REGENERON PHARMACEUTICALS INC 8,271 0.0571
ARKG 4 Aug 2021 Sell REGN REGENERON PHARMACEUTICALS INC 51,706 0.3535
ARKG 3 Aug 2021 Sell REGN REGENERON PHARMACEUTICALS INC 22,000 0.1472
ARKG 2 Aug 2021 Sell REGN REGENERON PHARMACEUTICALS INC 22,345 0.1502
ARKK 14 May 2021 Sell REGN REGENERON PHARMACEUTICALS INC 1,121 0.0030
ARKG 13 May 2021 Sell REGN REGENERON PHARMACEUTICALS INC 72,226 0.4938
ARKG 12 May 2021 Sell REGN REGENERON PHARMACEUTICALS INC 45,494 0.2995
ARKK 12 May 2021 Sell REGN REGENERON PHARMACEUTICALS INC 3,000 0.0077
ARKK 11 May 2021 Sell REGN REGENERON PHARMACEUTICALS INC 70,302 0.1755
ARKK 10 May 2021 Sell REGN REGENERON PHARMACEUTICALS INC 40,108 0.1014
ARKK 6 May 2021 Sell REGN REGENERON PHARMACEUTICALS INC 100,348 0.2435
ARKG 5 May 2021 Sell REGN REGENERON PHARMACEUTICALS INC 45,825 0.2529
ARKG 3 May 2021 Sell REGN REGENERON PHARMACEUTICALS INC 7,171 0.0375
ARKG 29 Apr 2021 Sell REGN REGENERON PHARMACEUTICALS INC 18,937 0.0948
ARKG 21 Apr 2021 Sell REGN REGENERON PHARMACEUTICALS INC 9,000 0.0473
ARKG 19 Apr 2021 Sell REGN REGENERON PHARMACEUTICALS INC 11,900 0.0633
ARKK 30 Mar 2021 Sell REGN REGENERON PHARMACEUTICALS INC 26,549 0.0594
ARKK 29 Mar 2021 Sell REGN REGENERON PHARMACEUTICALS INC 108,775 0.2538
ARKK 26 Mar 2021 Sell REGN REGENERON PHARMACEUTICALS INC 42,900 0.0900
ARKK 25 Mar 2021 Sell REGN REGENERON PHARMACEUTICALS INC 27,672 0.0595
ARKG 11 Mar 2021 Sell REGN REGENERON PHARMACEUTICALS INC 27,628 0.1318
ARKG 10 Mar 2021 Sell REGN REGENERON PHARMACEUTICALS INC 21,639 0.1089
ARKG 8 Mar 2021 Sell REGN REGENERON PHARMACEUTICALS INC 46,695 0.2482
ARKK 5 Mar 2021 Sell REGN REGENERON PHARMACEUTICALS INC 21,525 0.0462
ARKG 4 Mar 2021 Sell REGN REGENERON PHARMACEUTICALS INC 9,831 0.0459
ARKK 4 Mar 2021 Sell REGN REGENERON PHARMACEUTICALS INC 44,884 0.0927
ARKK 1 Mar 2021 Sell REGN REGENERON PHARMACEUTICALS INC 17,490 0.0326
ARKK 26 Feb 2021 Sell REGN REGENERON PHARMACEUTICALS INC 59,008 0.1131
ARKK 25 Feb 2021 Sell REGN REGENERON PHARMACEUTICALS INC 33,376 0.0642
ARKG 22 Feb 2021 Buy REGN REGENERON PHARMACEUTICALS INC 28,194 0.1084
ARKK 10 Feb 2021 Buy REGN REGENERON PHARMACEUTICALS INC 71,033 0.1297
ARKG 9 Feb 2021 Buy REGN REGENERON PHARMACEUTICALS INC 28,723 0.1131
ARKK 9 Feb 2021 Buy REGN REGENERON PHARMACEUTICALS INC 12,396 0.0225
ARKG 8 Feb 2021 Buy REGN REGENERON PHARMACEUTICALS INC 72,200 0.4261
ARKG 5 Feb 2021 Buy REGN REGENERON PHARMACEUTICALS INC 62,701 0.2621
ARKK 1 Feb 2021 Sell REGN REGENERON PHARMACEUTICALS INC 5,130 0.0111
ARKK 29 Jan 2021 Sell REGN REGENERON PHARMACEUTICALS INC 6,007 0.0100
ARKK 21 Jan 2021 Buy REGN REGENERON PHARMACEUTICALS INC 84,578 0.1919
ARKK 20 Jan 2021 Buy REGN REGENERON PHARMACEUTICALS INC 84,941 0.1954
ARKK 19 Jan 2021 Buy REGN REGENERON PHARMACEUTICALS INC 61,494 0.1500
ARKK 15 Jan 2021 Buy REGN REGENERON PHARMACEUTICALS INC 81,933 0.1910
ARKK 14 Jan 2021 Buy REGN REGENERON PHARMACEUTICALS INC 36,509 0.0800
ARKK 12 Jan 2021 Buy REGN REGENERON PHARMACEUTICALS INC 42,965 0.1025
ARKG 11 Jan 2021 Buy REGN REGENERON PHARMACEUTICALS INC 85,124 0.4505
ARKK 11 Jan 2021 Buy REGN REGENERON PHARMACEUTICALS INC 63,098 0.1517
ARKG 8 Jan 2021 Buy REGN REGENERON PHARMACEUTICALS INC 27,300 0.1483
ARKG 4 Jan 2021 Buy REGN REGENERON PHARMACEUTICALS INC 25,566 0.1631
ARKG 29 Dec 2020 Buy REGN REGENERON PHARMACEUTICALS INC 33,337 0.2188
ARKG 28 Dec 2020 Buy REGN REGENERON PHARMACEUTICALS INC 71,933 0.4569
ARKG 24 Dec 2020 Buy REGN REGENERON PHARMACEUTICALS INC 6,109 0.0384
ARKG 22 Dec 2020 Buy REGN REGENERON PHARMACEUTICALS INC 71,363 0.4855
ARKG 21 Dec 2020 Buy REGN REGENERON PHARMACEUTICALS INC 20,905 0.1570
ARKG 17 Dec 2020 Buy REGN REGENERON PHARMACEUTICALS INC 30,549 0.2486
ARKG 7 Dec 2020 Buy REGN REGENERON PHARMACEUTICALS INC 52,124 0.5067
ARKG 24 Nov 2020 Buy REGN REGENERON PHARMACEUTICALS INC 18,834 0.2744
ARKG 23 Nov 2020 Buy REGN REGENERON PHARMACEUTICALS INC 17,888 0.2555
ARKG 20 Oct 2020 Buy REGN REGENERON PHARMACEUTICALS INC 13,168 0.2571
ARKG 19 Oct 2020 Buy REGN REGENERON PHARMACEUTICALS INC 13,244 0.2549
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.